Dendritic Cell Vaccines
The immune system is a complex network of different cells that travel throughout the body. Leukocytes are all the cells in the blood that make up the immune system. This contains the cells: Lymphocytes, which are mainly Bone (B) and Thymus (T) cells. Other cells of the immune system include eosinophils, neutrophils, basophils, macrophages, microglia, natural killer cells, and also dendritic cells.
The immune system is divided into the innate and adaptive responses. Innate meaning it is present from birth and responds quickly to any foreign pathogens. Adaptive is slower but is responsible for maintaining immune responses and long-term memory. The dendritic cell is the mediator between these two areas.
Cells of the Immune System
The dendritic cell is the key mediator between the two branches of the immune system. These cells are designed to present foreign molecules (antigens) to T-cell lymphocytes, which will then go on to multiply and can either (1) attack the diseased, infected, or cancer cells directly or (2) activate B-cells to produce antibodies to help clear the body of the antigen or toxin.
With Dendritic Cell Therapy, we take the naive or unactivated DCs from the patient. In the laboratory setting, we can introduce these cells to many different proteins or molecules and put them in an environment to become activated. For Alzheimer's, we can introduce these cells to various proteins associated with the disease, such as amyloid beta. For Parkinson's, we can introduce these cells to the protein associated with this disease, alpha synuclein. These activated cells can then be reintroduced into the person, and these cell can then cause an appropriate immune response to clear these molecules and proteins from the body.
Dendritic Cell Therapy
Our Publications Related to DCs and DC Vaccines
Jan 2015 Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. Hum Vaccin Immunother.
Jan 2008 Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice. J Neuroimmunol.